Successful management of familial hemophagocytic lymphohistiocytosis by the JAK 1/2 inhibitor ruxolitinib.
Marois L, Touzot F, Haddad E, Fernandez I, Morin MP, De Bruycker JJ, et al. (2021). Successful management of familial hemophagocytic lymphohistiocytosis by the JAK 1/2 inhibitor ruxolitinib. Pediatr Blood Cancer. 68(6):e28954